Your browser doesn't support javascript.
loading
Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection.
Christie, Michael J; Irving, Aaron T; Forster, Samuel C; Marsland, Benjamin J; Hansbro, Philip M; Hertzog, Paul J; Nold-Petry, Claudia A; Nold, Marcel F.
Afiliación
  • Christie MJ; Department of Paediatrics, Monash University, Melbourne, Victoria 3168, Australia.
  • Irving AT; Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Victoria 3168, Australia.
  • Forster SC; Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Marsland BJ; Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Haining 314400, China.
  • Hansbro PM; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Melbourne, Victoria, Australia.
  • Hertzog PJ; Department of Molecular and Translational Sciences, Monash University, Melbourne, Victoria, Australia.
  • Nold-Petry CA; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.
  • Nold MF; Centre for Inflammation, Centenary Institute, Sydney, NSW 2050, Australia.
Sci Immunol ; 6(63): eabd0205, 2021 Sep 17.
Article en En | MEDLINE | ID: mdl-34533977
In humans, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is highly infective, often causes severe acute and/or long-term illness, and elicits a high rate of mortality, even in countries with sophisticated medical systems. Detailed knowledge on the immune responses underpinning COVID-19 (coronavirus disease 2019), and on strategies SARS-CoV-2 uses to evade them, can provide pivotal guidance to researchers and clinicians developing and administering potentially life-saving immunomodulatory therapies. The need for such therapies in COVID-19 is unlikely to abate soon given the emergence of variants of concern that may pose new challenges for some vaccines and neutralizing antibodies. Here, we summarize current knowledge on COVID-19 immunopathogenesis in relation to three clinical disease stages and focus on immune evasion strategies used by pathogenic coronaviruses such as skewing type I, II, and III interferon responses and inhibiting detection via pattern recognition and antigen presentation. Insights gained from bats, which exhibit minimal disease in response to SARS-CoV-2 infection, offer an informative perspective and may guide future development of new therapies. We also discuss how knowledge of immunopathology may inform therapeutic decisions, for example, on selecting the most appropriate immunotherapeutic agents and timing their administration, to reduce morbidity and mortality of COVID-19.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quirópteros / SARS-CoV-2 / COVID-19 / Factores Inmunológicos Tipo de estudio: Guideline / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Sci Immunol Año: 2021 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quirópteros / SARS-CoV-2 / COVID-19 / Factores Inmunológicos Tipo de estudio: Guideline / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Sci Immunol Año: 2021 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos